Kwality Pharmaceuticals share news and announcements
NSE: KPLBSE: 539997Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹3,618.30.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹3,661 Cr1,235th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 45.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 19 May 2026
- 11.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 27.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 25.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 19 May 2026
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 38,71643.8% delivered
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Kwality Pharmaceuticals quarterly results
The board met on 10 Aug 2026 to consider quarterly results
Notice filed 3 Aug 2026
Kwality Pharmaceuticals annual reports, presentations and earnings calls
The company's own documents, latest first.Kwality Pharmaceuticals financials, year by year
Annual reports11
- Annual report, year to Mar 2026 (opens in a new tab)9 Aug 2026
- Annual report, year to Mar 2025 (opens in a new tab)16 Aug 2025
- Annual report, year to Mar 2024 (opens in a new tab)31 Aug 2024
- Annual report, year to Mar 2023 (opens in a new tab)9 Sep 2023
- Annual report, year to Mar 2022 (opens in a new tab)7 Sep 2022
6 earlier reports
- Annual report, year to Mar 2021 (opens in a new tab)7 Sep 2021
- Annual report, year to Mar 2020 (opens in a new tab)6 Nov 2020
- Annual report, year to Mar 2019 (opens in a new tab)6 Sep 2019
- Annual report, year to Mar 2018 (opens in a new tab)15 Oct 2018
- Annual report, year to Mar 2017 (opens in a new tab)29 Oct 2017
- Annual report, year to Mar 2016 (opens in a new tab)8 Oct 2016
Investor presentations8
- Investor Presentation for quarter ended June 30, 2026. (opens in a new tab)10 Aug 2026
- Investor Presentation for the quarter and year ended 31st March, 2026. (opens in a new tab)19 May 2026
- Investor Presentation of Financial Results (opens in a new tab)12 Feb 2026
- Investor Presentation for FY 2025. (opens in a new tab)5 Jun 2025
- Investor Presentation of FY 24 RESULTS ATTACHED (opens in a new tab)27 May 2024
3 earlier presentations
Kwality Pharmaceuticals share news and announcements
373 announcements, routine notices left out, newest first. Page 1 of 8.
Oct 2026
Sep 2026
Aug 2026
9 Aug · Meeting
8 Aug · Corporate action
8 Aug · Meeting
3 Aug · Board meeting
Meeting on 10 Aug 2026: quarterly results
Jul 2026
24 Jul · Disclosure Under Regulation 30 Of SEBI LODR
Jun 2026
May 2026
8 May · Board meeting
Meeting on 19 May 2026: audited results and quarterly results
Mar 2026
30 Mar · Meeting
10 Mar · Update On Bioequivalence (BE) Program - Successful Completion Of Phase 1 By Kwality Pharmaceuticals Ltd.
Feb 2026
26 Feb · Meeting
14 Feb · Analysts
14 Feb · Analysts
2 Feb · Board meeting
Meeting on 12 Feb 2026: quarterly results
Jan 2026
1 Jan · Board meeting
Meeting on 1 Jan 2026
Dec 2025
1 Dec · Intimation Of Change In Name Of Managing Director Of The Company
Nov 2025
6 Nov · Board meeting
Meeting on 13 Nov 2025: quarterly results6 Nov · Successful Completion Of The EU-GMP Audit At Its Amritsar General And Beta-Lactam Units
Sep 2025
How the price met the news
The first session after each announcement, beside the market. Moves to 5 Feb 2026 are on BSE closes, before the company traded on NSE.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts).
- 3 Sep 2026Board or managers changeddown 1.13%−1.3 pts vs Nifty 500market median 0.0% · five sessions +5.5% (+6.7 pts vs Nifty 500) · volume 0.2× usual · delivery +1.7 pts against usual · The announcement (opens in a new tab)
- 3 Jun 2026Board or managers changedup 2.01%+2.3 pts vs Nifty 500market median 0.0% · five sessions +1.7% (+2.4 pts vs Nifty 500) · volume 0.4× usual · delivery +7.1 pts against usual · The announcement (opens in a new tab)
- 8 May 2026Credit ratingup 0.97%+1.4 pts vs Nifty 500market median 0.0% · five sessions −2.6% (−0.1 pts vs Nifty 500) · delivery −6.1 pts against usual · The announcement (opens in a new tab)
- 5 Feb 2026Board or managers changeddown 2.76%−2.2 pts vs Nifty 500market median 0.0% · five sessions −3.9% (−4.9 pts vs Nifty 500) · volume 1.4× usual · The announcement (opens in a new tab)
- 3 Feb 2026Board or managers changedup 8.27%+5.6 pts vs Nifty 500market median 0.0% · five sessions +10.9% (+7.2 pts vs Nifty 500) · volume 0.8× usual · The announcement (opens in a new tab)
- 29 Jan 2026Board or managers changedup 0.68%+0.5 pts vs Nifty 500market median 0.0% · five sessions +6.4% (+4.9 pts vs Nifty 500) · volume 0.2× usual · The announcement (opens in a new tab)
- 2 Jan 2026Board or managers changeddown 1.90%−2.7 pts vs Nifty 500market median 0.0% · five sessions −3.0% (−2.0 pts vs Nifty 500) · volume 0.3× usual · The announcement (opens in a new tab)
- 28 Jul 2025Board or managers changeddown 5.45%−4.7 pts vs Nifty 500market median 0.0% · five sessions −3.8% (−2.3 pts vs Nifty 500) · volume 1.1× usual · The announcement (opens in a new tab)
- 21 Sep 2022Credit ratingdown 3.53%−2.8 pts vs Nifty 500market median 0.0% · five sessions −15.8% (−11.0 pts vs Nifty 500) · volume 0.3× usual · The announcement (opens in a new tab)
- 23 Dec 2016Dividend0.00%0.0 pts vs Nifty 500market median 0.0% · five sessions −3.7% (−6.8 pts vs Nifty 500) · volume 4.5× usual
1 earlier announcement
- 13 Dec 2016Dividendup 4.99%+5.6 pts vs Nifty 500market median 0.0% · five sessions +5.7% (+9.6 pts vs Nifty 500) · volume 0.8× usual · The announcement (opens in a new tab)
Figures filed again
Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Total income | Quarter to Jun 2022 | Consolidated | 70.60 | 70.22 | −0.5% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Other expenses | Quarter to Jun 2022 | Consolidated | 10.31 | 10.31 | 0.0% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Total expenses | Quarter to Jun 2022 | Consolidated | 56.57 | 56.57 | 0.0% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Profit before tax | Quarter to Jun 2022 | Consolidated | 14.02 | 13.64 | −2.7% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Net profit | Quarter to Jun 2022 | Consolidated | 10.52 | 10.14 | −3.6% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Profit before one-off items and tax | Quarter to Jun 2022 | Consolidated | 14.02 | 13.64 | −2.7% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Net profit from continuing businesses | Quarter to Jun 2022 | Consolidated | 10.52 | 10.14 | −3.6% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Other comprehensive income | Quarter to Jun 2022 | Consolidated | −0.16 | −0.04 | +76.6% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Total comprehensive income | Quarter to Jun 2022 | Consolidated | 10.37 | 10.11 | −2.5% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Net profit belonging to the company's shareholders | Quarter to Jun 2022 | Consolidated | 10.54 | 10.17 | −3.5% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |